All Updates

All Updates

icon
Filter
Funding
Santa Ana Bio raises USD 168 million in Series A and B funding to advance anti-inflammatory programs to clinical trials
Precision Medicine
Jun 13, 2024
This week:
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
Precision Medicine
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
AI Drug Discovery
Yesterday
Partnerships
Beacon Therapeutics collaborates with Abeona Therapeutics for ophthalmic gene therapy development
Cell & Gene Therapy
Yesterday
Funding
Pan Cancer T raises EUR 4.25 million in seed extension funding for preclinical studies of PCT1:CO-STIM TCR T-cell therapy
Cell & Gene Therapy
Yesterday
Partnerships
Accelerated Biosciences and Pluristyx partner to create clinical-grade induced pluripotent stem cell lines
Cell & Gene Therapy
Yesterday
M&A
SoftBank acquires UK AI chipmaker Graphcore to improve AI capabilities
Edge Computing
Yesterday
Precision Medicine

Precision Medicine

Jun 13, 2024

Santa Ana Bio raises USD 168 million in Series A and B funding to advance anti-inflammatory programs to clinical trials

Funding

  • Santa Ana Bio has raised USD 168 million after Series A and B financing rounds. The Series A round, which raised USD 43 million, was led by Versant Ventures and saw participation from TPG's Life Science Innovations Fund and GV. The Series B round, which raised USD 125 million, was led by GV with new investors Andreessen Horowitz (a16z) Bio + Health, RTW, and Access Biotechnology.

  • The company plans to use these funds to advance two programs into clinical trials for inflammatory conditions by next year. It uses a proteomic, transcriptomic, and genomic approach that attempts to focus on disease-causing cells while sparing healthy ones, addressing ongoing shortcomings in trials such as patient heterogeneity, durability of response, and safety.

  • Santa Ana Bio is a biotechnology company focused on developing precision immunology solutions for autoimmune and inflammatory diseases by leveraging advanced multi-omics platforms and antibody engineering. The company’s pipeline includes several development-stage programs for multiple disease areas, including SAB01 for urticaria, food allergy, and asthma, and SAB 03 for rheumatoid arthritis, inflammatory bowel disease, asthma, and ankylosing spondylitis (axial spondyloarthritis).

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.